Identification of new types of biomarkers and tracers for the in vivo molecular imaging of the pancreatic Beta-cell mass
The goal of KeyMarker is to identify new types of biomarkers that can be used as radiotracers for PET or SPECT imaging and potential quantification of the pancreatic Beta-cell mass. Such molecules may lead to novel approaches for diabetic disease management, such as patient stratification, disease monitoring and therapeutic options. Several ligands for the target will be screened and evaluated through the preclinical models developed for the project. The in vitro/in vivo preclinical platform and the toxicology, bio-distribution and labelling expertise dedicated to the project form the groundwork for a standard process for further diabetes imaging tracer evaluation.
Consortium
Companies: IBA, Eurogentec, Trasis
Universities: Université Libre de Bruxelles, UCLouvain, ULiège, UNamur
